research use only

Pibrentasvir (ABT-530) HCV Protease inhibitor

Name: Pibrentasvir (ABT-530)
Brand: Selleck Chemicals
SKU: S9641
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S9641

Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor, with this compound exhibiting EC50 values ranging from 1.4 pM to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.

Chemical Structure

Molecular Weight: 1113.18

Jump to

Quality Control

Batch: S964101 DMSO]100 mg/mL]false]Ethanol]100 mg/mL]false]Water]Insoluble]false Purity: 98.35%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS
Datasheet

98.35

Related Targets	HDAC Caspase Proteasome Secretase MMP Cysteine Protease Tyrosinase DPP HIV Protease Serine Protease
Other HCV Protease Inhibitors	Danoprevir Lomibuvir (VX-222) Asunaprevir Tizoxanide PSI-6206 (GS-331007) 2'-C-Methylcytidine Tegobuvir Herba taxilli Extract Mecarbinate

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (89.83 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (4.49mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.830mg/ml (0.75mM)	Taking the 1 mL working solution as an example, add 50 μL of 16.6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	1113.18	Formula	C₅₇H₆₅F₅N₁₀O₈	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1353900-92-1	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CC(C(C(=O)N1CCCC1C2=NC3=C(N2)C=C(C(=C3)F)C4CCC(N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)C1CCCN1C(=O)C(C(C)OC)NC(=O)OC)NC(=O)OC)OC

Mechanism of Action

Targets/IC₅₀/Ki	GT5a (Cell-free assay) 1.4 pM(EC50) GT1a H77 (Cell-free assay) 1.8 pM(EC50) GT2b (Cell-free assay) 1.9 pM(EC50) GT4a (Cell-free assay) 1.9 pM(EC50) GT3a (Cell-free assay) 2.1 pM(EC50) GT2ab (Cell-free assay) 2.3 pM(EC50) GT6a (Cell-free assay) 2.8 pM(EC50) GT1b Con1 (Cell-free assay) 4.3 pM(EC50) GT2a JFH-1 (Cell-free assay) 5.0 pM(EC50)
In vitro	Pibrentasvir (ABT-530) is a next-generation HCV NS5A inhibitor with potent and pan-genotypic activity, and it maintains activity against common amino acid substitutions of HCV genotypes 1 to 6 that are known to confer resistance to currently approved NS5A inhibitors.
References	[1] https://pubmed.ncbi.nlm.nih.gov/28193664/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04577482	Completed	Hepatitis C Virus (HCV)	AbbVie	October 7 2020	--
NCT03303599	Completed	Hepatitis C	AbbVie	November 13 2017	--
NCT02441283	Completed	Hepatitis C	AbbVie	June 22 2015	Phase 2\|Phase 3
NCT02442258	Completed	Renal Impairment	AbbVie	March 2015	Phase 1
NCT02296905	Completed	Hepatic Impairment	AbbVie	October 2014	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):